TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma Apparent Clearance (CL/F) of Mepolizumab in Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crown survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of metabolic complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in high-sensitivity C-reactive protein (hs-CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection (HI titre ≥1:40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Posterior Capsule Opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Percentage of Agreement of Continuous Glucose Monitoring System Glucose Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of In-treatment Pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: cardio- and cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in PHQ-9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in Edinburgh Postnatal Depression Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WOMAC OA Index pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC OA Index physical function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of transient ischemic attack (TIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence rate of ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: remission rate of RA patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cummulative Incidence of Events at Week 26
Endpoint domain: Mortality/survival
Primary endpoint: Mortality (Number of Death)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in ICIQ-SF score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Graft Infection Requiring Re-operation
Endpoint domain: Adverse events/effects
Primary endpoint: Lung bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of patients who have acute appendicitis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of normal appendix
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of patients with alternative diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Mean percent change in inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Operative Hospital Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Combination of death and poor neurological function
Endpoint domain: Mortality/survival
Primary endpoint: Pelvic floor muscle sEMG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent accurate script related words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: alveolar ridge width gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraction Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of time patients are on the closed loop system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Goal Attainment Scale (GAS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in postoperative renal functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MR parameters in the tumor and surrounding area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive Outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Psychosocial Outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain/discomfort level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in elbow extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of Post-Operative Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Measure of Pain Level: VISA-P Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Measure of Activity Level: Tegner Activity Level Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Visual Analogue Scale (VAS) Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque reduction neutralization test (PNRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chest X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Amount of Weight Lost (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of Diabetic Status in the Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of Diabetic Status in Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in patient colitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change Score of ARAT Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change Score of FMA-UE Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: changes from baseline of areal BMD at lumbar spine and total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual clinical fracture incidence
Endpoint domain: Adverse events/effects
Primary endpoint: 1 month completion rate of the consult
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decline of Hepatitis D Virus (HDV) RNA Viral Titer of >2 Logs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Discontinuation of Medication
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of anastomotic leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Early detection of neurological abnormalities using MRS metabolic ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Early detection of neurological abnormalities using ABR parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bilirubin level and auditory abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bilirubin level and MRS abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximally tolerated dose determined by dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Dietary Quality Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) or maximum feasible dose (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period of detectability of NK-92/5.28.z cells in blood and cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Tumor Response Through Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the Timeline Follow-Back
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratio of pCDC2 Response in Skin Following Administration of Cytotoxic Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total active finger motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Development of Chronic Widespread Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS rating scale- Section III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venlafaxine Plasma Concentrations/Area-Under-the-Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic and cytogenetic remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of hematological and cytogenetic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maternal and foetal risk factors associated with uterine rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fear score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Global Health-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year
Endpoint domain: Mortality/survival
Primary endpoint: Total Radio-frequency (RF) Delivery Time During CFAE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average CO2 (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from documented AF/AT/AFL episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful completion of the return to play checklist
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects with a capture threshold increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Dose-limiting Toxicity (DLT) During Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Radiation Absorbed Doses by Organ for 177-Lu-cG250
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine cotinine analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving HbA1c Below 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-t of Tadalafil/ Tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events in HIV-negative adults
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of severe and non-severe COVID-19 disease in HIV-negative adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of adverse events in HIV-positive adults
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Wingate-test physical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood pressure and blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Strength Physical Performance (i.e., Handgrip)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pre-dose morning Peak Expiratory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial Pressure of Oxygen (PaO2 Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who achieved hemoglobin target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of obstructive sleep apnea syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Electroencephalographic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normal neurodevelopmental quotient at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jebsen Taylor Hand Function Test for Dominant Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jebsen Taylor Hand Function Test for Non-Dominant Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in central sympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Leukemic cell NF-kB activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: depressive complaints
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative Treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Equity of resource distribution
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PACU Visual Analogue Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total MME Intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Narcotic Use in PACU
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in estimated fitness assessment test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nutrition assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urodynamic parameters (Qmax, Voided volume, and PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUASS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevention of post operative nausea or vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SBA-MenC titre ≥ 1:8 (seroprotection status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PRP concentration ≥ 0.15 µg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SBA-MenC titre ≥ 1:128
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PRP concentration ≥ 1 μg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Agreement between self-reported and validated quality of life measurement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inattention and impulsivity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood lipids profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stage of retinopathy of prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Response rate based on severity of Raynaud's symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Score (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance obtained with six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of repetitions obtained with sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of HBV relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Identification of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain severity rating
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximum Concentration (Cmax) of Aprepitant in Participants 0 to <2 Years of Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of Aprepitant in Participants 0 to <2 Years of Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced at Least One Adverse Event (AE) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 10-2 visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in macular ganglion cell thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence and severity of CRBD
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical success at the post-therapy visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incident CVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants For Whom CXR Was Not Needed to Diagnose Pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Whose Pneumonia Was Missed by LUS or CXR
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative Draining Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Oral Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Retention of the final restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive, behavioural and emotional changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in breastmilk macronutrient composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in breastmilk micronutrient composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with cure or death
Endpoint domain: Mortality/survival
Primary endpoint: Ratio to Baseline in Urinary Protein Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of complete macroscopic resections (R0+R1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number and frequency of adverse events (nephro- or neurotoxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in The Graded Chronic Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apfel risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Participants With Post-operative Mechanical Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: step regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Weekly Average WI-NRS at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Weekly Average WI-NRS at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACP Knowledge Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ACP Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bone mineral density [g/cm2] of the 7 Gruen zones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone mineral density change relative to the baseline values of the 7 Gruen zones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant loosening or migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 6 Month Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in asthma Control Questionnaire (ACQ 6) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status